No abstract

The strategies for the management of MS were:. Changing the provider or buying a different packaging in 55 cases (39.9%). . Using a therapeutic alternative in 13 cases (9.4%).. Medicine imported from other countries through AEMPS authorisation was available in 26 cases (18.9%) but we only used it in 11 cases (8%) because of the need to repack each unit with a translated label and product data sheet before its distribution in the hospital. . Restricted use of available pharmacy stock in 14 cases (10.1%), according to clinical criteria agreed with medical staff. . No action was needed in 45 cases (30.6%) due to infrequent use of the medicine affected and/or enough pharmacy stock available until resupply.